URIC ACID AND HYPERTENSION IN AFRICAN-AMERICANS

非裔美国人的尿酸和高血压

• 批准号: 7950718
• 负责人: MARK R SEGAL
• 金额: $ 11.87万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7950718
• 关键词: Adverse effects; African American; Allopurinol; Blood Pressure; Body Composition; Chlorthalidone; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Diuretics; Double-Blind Method; Functional disorder; Funding; Gout; Grant; Hyperlipidemia; Hypertension; Hyperuricemia; Incidence; Inflammation; Institution; Insulin Resistance; Kidney; Measures; Metabolic; Patients; Placebo Control; Placebos; Randomized; Research; Research Personnel; Resources; Sodium-Restricted Diet; Source; Staging; Testing; Thiazide Diuretics; Treatment Protocols; United States National Institutes of Health; Uric Acid; blood pressure regulation; hemodynamics; hypertension treatment; impaired glucose tolerance; oxidant stress; thiazide; xanthine oxidase inhibitor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Thiazide diuretics when used in the treatment of hypertension are associated with many metabolic side effects including hyperuricemia, gout, insulin resistance, and hyperlipidemia. Each of these conditions is already highly prevalent in African-Americans. Our hypothesis is that thiazide-induced hyperuricemia decreases the efficacy of thiazides in controlling BP, leads to endothelial dysfunction, and increases the incidence of insulin resistance and impaired glucose tolerance. This hypothesis will be tested in a randomized double-blind placebo-controlled 2 ¿ 2 factorial clinical trial of 8-week duration in which a total of 300 African-Americans patients with stage 1 hypertension, BP: 140-159/90-99 mm Hg, will be assigned to one of four regimens: a thiazide-like diuretic, chlorthalidone 25 mg/day, and a xanthine oxidase inhibitor, allopurinol; chlorthalidone 25 mg/day and placebo; placebo; or allopurinol in conjunction with a low-sodium diet. The primary end-point is reduction in systolic BP. Secondary end-points measure endothelial function, ambulatory blood pressure, body composition, systemic inflammation, metabolic parameters, oxidant stress and renal hemodynamics.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 噻嗪类利尿剂在用于治疗高血压时与许多代谢副作用相关，包括高尿酸血症、痛风、胰岛素抵抗和高脂血症。这些情况在非洲裔美国人中已经非常普遍。我们的假设是噻嗪类药物诱导的高尿酸血症降低了噻嗪类药物控制血压的效果，导致内皮功能障碍，并增加胰岛素抵抗和糖耐量受损的发生率。 该假设将在一项为期8周的随机双盲安慰剂对照2 - 2析因临床试验中进行检验，在该试验中，共有300名患有1期高血压（BP：140-159/90-99 mm Hg）的非洲裔美国人患者将被分配至四种治疗方案之一：噻嗪类利尿剂氯噻酮25 mg/天和黄嘌呤氧化酶抑制剂别嘌呤醇; 氯噻酮25 mg/天和安慰剂;安慰剂; 或 别嘌呤醇和低钠饮食主要终点是收缩压降低。次要终点测量内皮功能、动态血压、身体组成、全身炎症、代谢参数、氧化应激和肾血流动力学。